Mr. Basta has more than 25 years of leadership experience in the biopharmaceutical and medical device industry. Mr. Basta served as CEO of SaNOtize, a company that develops and commercializes anti-infective therapies since 2023. SaNOtize has recently launched novel nitric oxide-based topical infection products in the US. Prior to this role, he served as CEO of Mahana Therapeutics, a prescription digital therapeutic company which launched the first FDA-approved digital app treatment for irritable bowel syndrome and developed a novel digital therapy for tinnitus. He previously served as CEO of Menlo Therapeutics (now VYNE Therapeutics), AlterG, BioForm Medical and its successor Merz Aesthetics. During his tenure at BioForm Medical and later Merz Aesthetics Mr. Basta built a leading worldwide medical aesthetics business with industry-leading innovations in product design, new applications, and commercial strategies.
He currently serves on the board of directors of DermBiont, Inc. and VYNE Therapeutics.
Mr. Basta holds an MBA from the Kellogg Graduate School of Management at Northwestern University and a BA in Biomedical Engineering from Johns Hopkins University.